未接种疫苗且HPV阴性的老年女性末次筛查年龄与宫颈癌余生风险:一项建模研究
该建模研究用马尔可夫模型估计不同末次筛查年龄和不同退出筛查检测下老年未接种疫苗女性宫颈癌的余生风险。模型预测从未筛查者余生风险为1/45,70岁女性若HPV检测阴性余生风险可降至1/6525。作者认为细胞学筛查至75岁可能降低风险,但获益递减。
要点
- 从未筛查的未接种疫苗女性余生宫颈癌风险为1/45(95%百分位区间1/32至1/64)。
- 70岁女性若HPV检测阴性,余生风险降至1/6525(降低12.9倍)。
- 细胞学筛查停止年龄从55岁延至75岁可使晚年癌症风险进一步降低,但获益递减。
核心结论
- 将细胞学筛查延至75岁可能实现宫颈癌风险降低,但获益递减。
- 55岁以上有宫颈的未接种疫苗女性,退出时致癌HPV检测阴性或HPV加细胞学阴性均与低余生宫颈癌风险相关。
研究设计与样本
- 建模研究,建立宫颈癌自然史与筛查的状态转移(马尔可夫)模型。
- 模型用加拿大省级登记和调查数据开发、校准和验证,数据来自加拿大统计局汇总的13个省级登记。
- 每年新入组236564名女性(2012年加拿大20-24岁女性人口的五分之一),从10岁进入模型,构建10-100岁年龄结构人群。
- 全子宫切除女性被排除分析。
- 采用三阶段渐进性宫颈上皮内瘤变模型,并按四种高危HPV组建模感染。
主要发现
- 排除全子宫切除女性后,80-84岁女性宫颈癌发病率被低估最多达71%。
- 从未筛查的未接种疫苗女性余生宫颈癌风险为1/45(95%百分位区间1/32至1/64)。
- 25-69岁每3年细胞学筛查完全依从(100%女性筛查)可使未接种疫苗女性余生风险降至1/532(95%百分位区间1/375至1/820)。
- 细胞学筛查停止年龄从55岁增至75岁导致晚年癌症风险逐步降低。
- 筛查史未知的70岁女性若停止筛查,平均余生风险为1/588(<1%;95%百分位区间1/451至1/873)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a paucity of empirical evidence to inform the age at which to stop cervical cancer screening. The recommended age to stop screening generally varies between age 50-70 years worldwide. However, cervical cancer incidence and mortality remain high in older women. We used a Markov model of cervical cancer screening to estimate the remaining lifetime risk of cervical cancer at different ages and with different exit screening tests, with the aim of informing recommendations of the age at which to stop cervical cancer screening in developed countries. METHODS: For this modelling study, we developed a state transition (Markov) model of cervical cancer natural history and screening. We developed, calibrated, and validated our model using Canadian provincial registries and survey data. To simulate an age-structured population in the model, a new cohort of 236 564 women (one fifth of the population of Canadian women aged 20-24 years in 2012) entered the model every year and were successively modelled in parallel. Successive cohorts entered the model at age 10 years, creating an age-structured population of women aged 10-100 years. Women who had a total hysterectomy were excluded from the analyses. We calibrated our model to human papillomavirus (HPV) infection and cancer incidence with data from Statistics Canada, which compiles the data from 13 individual provincial registries. We chose a three-stage progressive cervical intraepithelial neoplasia model to include differences in management and treatment decisions depending on lesion severity. We modelled infections with four high-risk HPV groups: HPV16 and HPV18; HPV31, HPV33, HPV45, HPV52, and HPV58; HPV35, HPV39, HPV51, HPV56, HPV59, HPV66, and HPV68; and a generic group of other potentially oncogenic HPVs. We estimated 5-year, 10-year, and remaining lifetime risk of cervical cancer for older, unvaccinated women who stopped screening at different ages and underwent different screening tests. FINDINGS: Cervical cancer incidence excluding women with hysterectomies underestimated the incidence of cervical cancer in women with a cervix by up to 71% in women aged 80-84 years. Our model predicted that women without HPV vaccination who have been never screened have a 1 in 45 (95% percentile interval 1 in 32 to 1 in 64) lifetime risk of cervical cancer. Perfect adherence (100% of women screened) to cytology screening every 3 years between the ages of 25 years and 69 years could reduce the lifetime risk of cervical cancer to 1 in 532 women (95% percentile interval 1 in 375 to 1 in 820) without HPV vaccination. Increasing the age at which women stopped cytology screening from 55 years to 75 years led to incremental decreases in cancer risk later in life. A 70-year old woman whose screening history was unknown had an average remaining lifetime risk of 1 in 588 (<1%; 95% percentile interval 1 in 451 to 1 in 873) if she stopped screening. Her remaining lifetime risk at age 70 years was reduced to 1 in 1206 (2·0 times reduction; 95% percentile interval 1 in 942 to 1 in 1748) if she had a negative cytology test, 1 in 6525 (12·9 times reduction; 95% percentile interval 1 in 3167 to 1 in 18 664) if she had a negative HPV test, and 1 in 9550 (18·1 times reduction; 95% percentile interval 1 in 4928 to 1 in 23 228) if she had a negative co-test for cytology and HPV. INTERPRETATION: Cervical cancer risk reductions might be achieved by screening with cytology up to age 75 years, although with diminishing returns. A negative exit oncogenic HPV test or negative HPV test plus cytology correlates with a low remaining lifetime cervical cancer risk for unvaccinated women with a cervix after the age of 55 years. FUNDING: Canadian Institutes of Health Research.
引用
- Malagón T, Kulasingam S, Mayrand MH, et al. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study. Lancet Oncol. 2018. PMID: 30392810. doi:10.1016/S1470-2045(18)30536-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。